BayBio Joins Senator Yee to Push for Smoking Cessation R&D

BayBio CEO Gail Maderis joined state Senator Leland Yee at San Francisco General Hospital to advocate health providers to cover smoking cessation treatments like patches, inhalers and prescription medications. According the US Surgeon General, tobacco use is the single greatest cause of disease and premature death in America today and is responsible for more than 435,000 deaths annually. Yet, providers do not reward those working to put an end to this deadly habit. Detailed Information.

BayBio Continues Advocacy Push with Congresswoman Speier Roundtable

Just one week after meeting Rep. James Clyburn, members of BayBio met with Rep. Jackie Speier on Friday March 5 to discuss several relevant issues, in particular to generate support for funding-strapped companies. Due to the looming financial climate, many companies are seeking new funding sources that traditionally come from private investors or the public markets. As part of the healthcare reform discussion Sen. Menendez introduced a measure to provide incentives for companies with 250 employees or less that would provide grant funding for their research and development activity. Rep. Speier said that this measure was still included in the reform package and was supportive of the organization’s activities. To participate in future meetings, email travis@baybio.org.

March 17 BayBio NEST | 7th Annual Life Sciences Investors & Entrepreneur Roundtables
March 23 BioFacilities | Industry Knowledge for the Non-Scientist
March 25 Therapeutic Breakfast Series | Establishing and Successfully Managing Strategic Alliances
April 7 BayBio2010 | Life Science Innovation: Drivers and Barriers
April 15 BayBio NEST | A Tailor Made Approach: Personalized Medicine
April 22 Therapeutic Breakfast Series | Preparing for Coverage & Reimbursement: Demonstrating Value
April 29 BayBio NEST | Technology Showcase at SRI International
May 11 Medical Device Breakfast Series | How the FDA's 510(k) Programs Are Changing
May 12 BayBio Executive Series | Managing the Board
May 19 California Life Sciences Day

Takeda San Francisco
Center for Excellence in Therapeutic Antibody Research

Takeda San Francisco, Inc.(TSF) is Takeda's global center for excellence for biologics. TSF was established in November 2007 and supports Takeda's therapeutic antibody research through our antibody technology platform. This platform is based on discovery, optimization and development technologies used to efficiently generate Investigational New Drug (IND) candidates for the treatment of cancer, inflammatory and metabolic diseases.

• Learn more about Takeda San Francisco